Croma-Pharma Expands Successful Mask Range With Face Masks for Different Areas of Application
21.10.2021 12:38:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) announced today the expansion of its successful mask portfolio. The carefully selected ingredients of each formulation, as well as the sheet material, are tailored to specific application areas and skin needs. The products have a pleasant texture and are suitable for all skin types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005468/en/
@Croma (Photo: Business Wire)
The right mask for every need
The Croma mask portfolio offers two full face masks, as well as masks for specific areas of the face including the eyes, lips, and laugh lines.
Calming face mask with aloe vera, green tea and rosehip oil
The Croma calming face mask contains ingredients known for their antioxidant and soothing effects, as well as skin-regenerating properties. It replenishes the skin with vitamins and helps to protect against harmful environmental influences. Regular use may help to strengthen the skin barrier and provides optimal care for the skin. The material consists of 80 percent green tea fibers and 20 percent cupro - so not only the serum per se works to achieve the desired effect, but also the mask material itself.
Key ingredients: hyaluronic acid, rosehip oil, green tea leaf extract, aloe vera juice
Recommended retail price: EUR 59,-
Rejuvenating face mask with hyaluronic acid
This hyaluronic acid mask has long been considered to be one of Croma Pharma Skincare's most popular products. The incorporated ingredients refresh dehydrated skin, alleviate visible dryness and help to improve the skin’s elasticity. In addition to its pleasant cooling effect, the formulation may help to smooth small wrinkles and ensures a radiant complexion. Regular use can help to fight the signs of skin aging and maintain a youthful appearance.
Key ingredients: hyaluronic acid, imperata cylindrica root extract, irish moss extract
Recommended retail price: EUR 59,-
Organic cellulose masks for special facial areas
Energizing eye mask with hyaluronic acid, kiwi and cucumber extract
Croma energizing eye mask provides an instant boost of hydration. The mask is packed with soothing ingredients which sustainably improve the skin barrier function and skin elasticity. The fermented extracts nourish the skin with valuable postbiotics. The eye mask contains powerful antioxidants – including vitamin C – and helps to moisturize and reduce signs of fatigue, while providing an extra energy kick for a fresh and energized appearance.
Key ingredients: hyaluronic acid, kiwi fruit ferment, cucumber extract
Recommended retail price: EUR 55,-
Regenerating lip mask with hyaluronic acid, aloe vera and berry ferment
The regenerating lip mask infused with hyaluronic acid, aloe vera and berry ferment that deeply moisturize the delicate lip area while providing a cooling and regenerating effect. The ingredients soften and plump the lips.
Key ingredients: hyaluronic acid, aloe vera, berry ferment
Recommended retail price: EUR 55,-
Firming laugh line mask with hyaluronic acid and pomegranate extract
Croma firming mask for laugh lines is enriched with hyaluronic acid to intensely hydrate and soothe the skin of the nasolabial folds. The carefully selected ingredients include Palmitoyl hexapeptide, a biomimetic peptide that gives a firming effect and can smooth the appearance of wrinkles. Pomegranate ferment extract, a potent antioxidant, may increase skin collagen.
Key ingredients: hyaluronic acid, palmitoyl hexapeptide-12, pomegranate fermented extract
Recommended retail price: EUR 55,-
Croma expert tip - the right application
Croma Expert Tip by Dr. Monika Sulovsky, Yuvell® Committed to Beauty: “A moisturizing mask is a freshness boost for any skin type and can easily be applied in the morning or evening.
- Step 1: A face mask is always applied to a cleansed face and is used before serums or creams.
- Step 2: The mask should be left on for 15 minutes.
- Step 3: Finally, remove the mask and gently massage the excess serum into the skin.”
“Our Croma face masks have been very popular for a long time. This was also a welcome occasion for us to expand the portfolio in order to be able to offer our customers a comprehensive beauty treatment at home", explains Andreas Prinz, the Managing Director of Croma-Pharma.
Availability
The Croma masks are available via www.cromaskincareshop.com and selected partners.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses its own branded products on minimally invasive aesthetic medicine. In addition to a broad range of HA fillers produced on site, Croma also markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005468/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom